Syndecan-1蛋白在皮肤鳞状细胞癌的表达及意义

摘要/Abstract

摘要：

目的检测皮肤鳞状细胞癌（鳞癌）患者血清可溶性多配体蛋白聚糖1（SDC1）水平和SDC1蛋白在组织中的表达及两者的相关性。方法免疫组化方法检测93例鳞癌及30例健康对照者表皮SDC1的表达，酶联免疫吸附测定（ELISA）检测81例鳞癌患者和30例健康对照者血清中可溶性SDC1的表达水平。结果鳞癌组织中，SDC1表达明显低于健康对照组（Z = 3.85，P < 0.01）。在不同肿瘤厚度和分化程度的鳞癌中，SDC1表达强度随肿瘤厚度的增加和分化程度地降低而有下降趋势（χ2分别为11.66和12.51，均P < 0.01）。鳞癌患者中伴淋巴结转移组SDC1表达强度显著低于无淋巴结转移组（Z = 2.20，P < 0.05）。鳞癌患者血清可溶性SDC1表达水平显著高于健康对照组（Z = 4.12，P < 0.01），且随着肿瘤厚度的增加和临床分期的变晚血清可溶性SDC1水平逐渐升高。侵袭性鳞癌的SDC1水平高于原位鳞癌的患者（Z = 3.02，P < 0.01），但不同分化程度的侵袭性鳞癌血清SDC1水平比较，差异无统计学意义（均P > 0.05）。有淋巴结转移的鳞癌患者血清SDC1水平明显高于无淋巴结转移组（Z = 5.30，P < 0.01）。鳞癌患者血清中可溶性SDC1的水平与组织中SDC1表达强度呈负相关（rs = -0.625，P < 0.01）。用受试者工作曲线法判断血清可溶性SDC1水平对诊断有无淋巴结转移的最佳临界点为65.5 μg/L，其敏感度为73.7%，特异度为87.1%，曲线下面积值为0.904（0.840 ~ 0.968）。结论鳞癌组织中，SDC1表达减弱和血清中可溶性SDC1水平升高与鳞癌的侵袭性相关，血清SDC1水平升高对鳞癌患者淋巴结转移的诊断具有一定的价值。

Abstract:

Sun Yi, Wang Zhenhua, Wang Rongrong, Zhang Yunxiang Department of Dermatology, Weifang People′s Hospital, Weifang 261041, Shandong, China（Sun Y, Wang ZH）; Clinical Laboratory, Weifang People′s Hospital, Weifang 261041, Shandong, China（Wang RR）; Department of Pathology, Weifang People′s Hospital, Weifang 261041, Shandong, China （Zhang YX） Corresponding author: Wang Zhenhua, Email: wfzcwzh@126.com 【Abstract】 Objective To measure serum and tissue levels of soluble syndecan-1 （SDC1） in patients with cutaneous squamous cell carcinoma （CSCC）, and to explore the relationship between the expression of SDC1 and clinicopathologic features of CSCC as well as between the serum and tissue levels of SDC1. Methods An immunohisto-chemical study was performed to measure SDC1 expression in the epidermis of lesional specimens from 93 patients with CSCC and normal skin specimens from 30 healthy human controls, and enzyme-linked immunosorbent assay （ELISA） to detect serum levels of soluble SDC1 in 81 patients with CSCC and 30 healthy human controls. Results The expression of SDC1 was significantly lower in CSCC tissues than in normal skin tissues （Z = 3.85, P < 0.01）. The expression intensity of SDC1 decreased with the increase in tumor thickness but with the decrease in degree of differentiation of CSCC （χ2 = 11.66, 12.51 respectively, both P < 0.01）. Furthermore, the expression of SDC1 was significantly lower in lesional tissues of CSCC with lymph node metastasis than in those without （Z = 2.20, P < 0.05）. As ELISA showed, serum levels of soluble SDC1 were significantly higher in patients with CSCC than in healthy controls （Z = 4.12, P < 0.01）, and gradually increased with the increase in tumor thickness and with advancing clinical stages of CSCC. In addition, serum levels of SDC1 were significantly up-regulated in patients with invasive CSCC compared with those with CSCC in situ （Z = 3.02, P < 0.01）, but were not significantly different among patients with invasive CSCC at different degrees of differentiation （P > 0.05）. CSCC patients with lymphatic metastasis showed significantly higher serum levels of SDC1 compared with those without （Z = 5.30, P < 0.01）. The serum levels of soluble SDC1 were significantly negatively correlated with its tissue levels in CSCC patients （rs = －0.625, P < 0.01）. Receiver operating characteristic （ROC） curve analysis showed that the best cut-off point of serum SDC1 levels was 65.5 μg/L for the diagnosis of lymphatic metastasis, with the sensitivity, specificity and area under the curve（AUC） being 73.7%, 87.1% and 0.904（0.840 - 0.968） respectively. Conclusion The down-regulated tissue expression but up-regulated serum levels of SDC1 may be associated with the invasiveness of CSCC, and elevated serum SDC1 levels are somewhat valuable to the diagnosis of lymphatic metastasis.

孙怡王振华王荣荣张云香. Syndecan-1蛋白在皮肤鳞状细胞癌的表达及意义[J]. 中华皮肤科杂志, 2016, 49(2): 98-102.doi:

参考文献 15

［1］	Kozma B, Eide MJ. Photocarcinogenesis: an epidemiologic perspec⁃tive on ultraviolet light and skin cancer［J］. Dermatol Clin, 2014, 32（3）: 301⁃313. DOI: 10.1016/j.det.2014.03.004.
［2］	Teng YH, Aquino RS, Park PW. Molecular functions of syndecan⁃1 in disease［J］. Matrix Biol, 2012, 31（1）: 3⁃16. DOI: 10.1016/j.matbio.2011.10.001.
［3］	Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan⁃1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer［J］. Cancer Res, 2002, 62（18）: 5210⁃5217.
［4］	Nault JC, Guyot E, Laguillier C, et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis［J］. Cancer Epidemiol Biomarkers Prev, 2013, 22（8）: 1343⁃1352. DOI: 10.1158/1055⁃9965.EPI⁃13⁃0179.
［5］	Mundt F, Heidari⁃Hamedani G, Nilsonne G, et al. Diagnostic and prognostic value of soluble syndecan⁃1 in pleural malignancies［J］. Biomed Res Int, 2014, 2014: 419853. DOI: 10.1155/2014/419853.
［6］	Wang X, Zuo D, Chen Y, et al. Shed Syndecan⁃1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer［J］. Br J Cancer, 2014, 111（10）: 1965⁃1976. DOI: 10.1038/bjc.2014.493.
［7］	Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan⁃1 is an independent risk factor for poor survival in bladder cancer［J］. Hum Pathol, 2014, 45（4）: 674⁃682. DOI: 10.1016/j.humpath.2013.10.036.
［8］	Ramani VC, Purushothaman A, Stewart MD, et al. The heparanase/syndecan⁃1 axis in cancer: mechanisms and therapies［J］. FEBS J, 2013, 280（10）: 2294⁃2306. DOI: 10.1111/febs.12168.
［9］	席银雪, 宋鑫, 陈洁, 等. syndecan⁃1在胃黏膜癌变不同阶段组织中的表达及意义［J］. 中华肿瘤杂志, 2007, 29（3）: 193⁃196. DOI: 10.3760/j.issn:0253⁃3766.2007.03.008.
	Xi YX, Song X, Chen J, et al. Expression of syndecan-1 at different stages in the course of gastric carcinoma and its significance［J］. Chin J Oncol, 2007（3）: 193-196. DOI: 10.3760/j.issn:0253-3766.2007.03.008.
［10］	Roh YH, Kim YH, Choi HJ, et al. Fascin over correlates with positive thrombospondin⁃1 and syndecan⁃1 s and a more aggressive clinical course in patients with gallbladder cancer［J］. J Hepatobiliary Pancreat Surg, 2009, 16（3）: 315⁃321. DOI: 10.1007/s00534⁃009⁃0046⁃1.
［11］	Kurokawa H, Zhang M, Matsumoto S, et al. Reduced syndecan⁃1 is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma［J］. J Oral Pathol Med, 2006, 35（5）: 301⁃306.
［12］	Ro Y, Muramatsu T, Shima K, et al. Correlation between reduction of syndecan⁃1 and clinico⁃pathological parameters in squamous cell carcinoma of tongue［J］. Int J Oral Maxillofac Surg, 2006, 35（3）: 252⁃257.
［13］	Wang JB, Guan J, Shen J, et al. Insulin increases shedding of syndecan⁃1 in the serum of patients with type 2 diabetes mellitus［J］. Diabetes Res Clin Pract, 2009, 86（2）: 83⁃88. DOI: 10.1016/j.diabres.2009.08.002.
［14］	Yablecovitch D, Stein A, Shabat⁃Simon M, et al. Soluble syndecan⁃1 levels are elevated in patients with inflammatory bowel disease［J］. Dig Dis Sci, 2015, 60（8）: 2419⁃2426. DOI: 10.1007/s10620⁃015⁃3589⁃9.
［15］	Kim KJ, Kim JY, Baek IW, et al. Elevated serum levels of syndecan⁃1 are associated with renal involvement in patients with systemic lupus erythematosus［J］. J Rheumatol, 2015, 42（2）: 202⁃209. DOI: 10.3899/jrheum.140568.